This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen’s single dose vaccine gains Emergency Use Authorization; There’s findings on the effectiveness of ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.
Lorbrena is a third generation ALK tyrosine kinase inhibitor.
Pafolacianine sodium binds to folate receptors commonly found on many cancers, including ovarian and lung cancers, and illuminates the cancerous lesions under near-infrared light.
Review of meta-analyses of prospective observational studies reveals lower risk with higher intakes of dietary fiber, dietary calcium, yogurt
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
Oblato plans to evaluate OKN-007 for diffuse intrinsic pontine glioma in a phase 1/2 trial this year.
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.
Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.
Management approach to these findings includes axillary ultrasound if clinical concern persists six weeks after final dose of vaccine
